Clinical trialNCT06707493RecruitingPhase 2Interventional

Ivosidenib as Post-HSCT Maintenance for AML

SponsorMassachusetts General HospitalEnrollment75Acute Myeloid Leukemia (AML)Hematopoietic Stem Cell Transplant (HSCT)IDH1 Mutation

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Amir T Fathi, MD
Massachusetts General Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory University Hospital
Atlanta, Georgia, United States
Amelia Langston, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Robert Soiffer, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Amir Fathi, MD
Recruiting
Ohio State University Wexner Medical Center- James Cancer Hospital
Columbus, Ohio, United States
Jiasheng Wang, MD
Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Sagar Patel, MD
Recruiting
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Sameem Abedin, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ivosidenib →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Jan 2026
Primary completion: 1 Jan 2028
Completion: 1 Jan 2030
Last update posted: 18 Jun 2026
Registered enrollment: 75
Registry id: NCT06707493

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.